# 14.2 AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE, amino acid formula with vitamins and minerals without phenylalanine oral liquid, 30 x 125 mL cans,

# PKU Lophlex LQ 20®, Nutricia Australia Pty Ltd

**AMINO ACID FORMULA with VITAMINS and MINERALS without PHENYLALANINE, amino acid formula with vitamins and minerals without phenylalanine oral liquid, 60 x 62.5 mL cans,**

**PKU Lophlex LQ 10®, Nutricia Australia Pty Ltd**

1. **Purpose of application**
	1. To inform the PBAC of additional flavour variants and minor nutritional upgrades within the currently listed PKU Lophlex LQ 10 and PKU Lophlex LQ 20 products for treatment of patients with phenylketonuria (PKU).

No changes to the current PBS listings are requested.

1. **Background**
	1. These products are currently PBS listed as Restricted Benefits for phenylketonuria.
	2. Nutricia has extended its range of PKU Lophlex LQ 10 and 20 products with the addition of new flavours ''' ''''''''''' ''''''''''''''''''' ''''''''' '''''''''''' '''''''''''''', to complement the existing flavour range. These new flavours have been formulated using the same macronutrient and micronutrient profile as existing flavours with the following exceptions:
* ''''''''''''''''''''''''' '''''''''''''''' '''' in line with latest recommendation on requirements
* '''''''''''''' ''''''''''' ''''' ''''''''' ''''''''' in line with recommendations for the general population



No changes to price or current PBS listing were requested in the submission.

1. **PBAC Outcome**
	1. The PBAC noted that the Nutritional Products Working Party had no objection to the two new flavours being made available through the PBS under the existing listings for PKU Lophlex LQ 10 and PKU Lophlex LQ 20. The PBAC accepted the changes.
2. **Context for Decision**

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

1. **Sponsor’s Comment**

The sponsor had no comment.